10434
|
ETCTN
|
Randomized Phase 2 Study of CPX-351 + Pomalidomide versus CPX-351 in Newly Diagnosed AML with MDS-Related Changes
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10437
|
ETCTN
|
A Single Arm Phase II Study of Bone-targeted Sn-117m-DTPA in Symptomatic Castration Resistant Prostate Cancer with Skeletal Metastases
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
10440
|
ETCTN
|
A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10445
|
ETCTN
|
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10449
|
ETCTN
|
A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10450
|
ETCTN
|
A Phase 1b Trial of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10464
|
ETCTN
|
A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10466
|
ETCTN
|
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10476
|
ETCTN
|
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10479
|
ETCTN
|
A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|